BakhtiyariMSchmidtNHadaeghFet al.Direct and indirect effects of central and general adiposity on cardiovascular diseases: The Tehran Lipid and Glucose Study. Eur J Prev Cardiol2018; 25: 1170–1181.
2.
FinocchiaroGPapadakisMDhutiaHet al.Obesity and sudden cardiac death in the young: Clinical and pathological insights from a large national registry. Eur J Prev Cardiol2018; 25: 395–401.
3.
GarnvikLEMalmoVJanszkyIet al.Physical activity modifies the risk of atrial fibrillation in obese individuals: The HUNT3 study. Eur J Prev Cardiol2018; 25: 1646–1652.
4.
FrederixISolmiFPiepoliMFet al.Cardiac telerehabilitation: A novel cost-efficient care delivery strategy that can induce long-term health benefits. Eur J Prev Cardiol2017; 24: 1708–1717.
5.
JørgensenMEAnderssonCVasanRSet al.Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: A systematic review and meta-analyses. Eur J Prev Cardiol2018; 25: 366–376.
6.
KeenanJ. Improving adherence to medication for secondary cardiovascular disease prevention. Eur J Prev Cardiol2017; 24(3 Suppl.): 29–35.
7.
De BackerGG. Prevention of cardiovascular disease: Much more is needed. Eur J Prev Cardiol2018; 25: 1083–1086.
8.
TunonJBackMBadimonLet al.Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. Eur J Prev Cardiol2018; 25: 948–955.
9.
ZentiMGAltomariALupoMGet al.From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol2018; 25: 1843–1851.
10.
PecinIHartgersMLHovinghGKet al.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol2017; 24: 1383–1401.
11.
Van KleefMESpieringW. Hypertension: Overly important but under-controlled. Eur J Prev Cardiol2017; 24: 36–43.
12.
EylesHMcLeanRNealBet al.A salt-reduction smartphone app supports lower-salt food purchases for people with cardiovascular disease: Findings from the SaltSwitch randomised controlled trial. Eur J Prev Cardiol2017; 24: 1435–1444.
13.
ProiettiMMairesseGHGoethalsPet al.Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. Eur J Prev Cardiol2017; 24: 328–334.
14.
CoppettiTBrauchlinAMugglerSet al.Accuracy of smartphone apps for heart rate measurement. Eur J Prev Cardiol2017; 24: 1287–1293.
15.
AimoAGiannoniACastiglioneVet al.Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. Eur J Prev Cardiol2017; 24: 1718–1724.
16.
HuangYHChenCMLeeYSet al.Detection of mitochondrial DNA with 4977 bp deletion in leukocytes of patients with ischemic stroke. PLoS One2018; 13: e0193175–e0193175.
17.
MontLPellicciaASharmaSet al.Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Eur J Prev Cardiol2017; 24: 41–69.
18.
GrazioliGSanz de la GarzaMVidalBet al.Prevention of sudden death in adolescent athletes: Incremental diagnostic value and cost-effectiveness of diagnostic tests. Eur J Prev Cardiol2017; 24: 1446–1454.
